Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3) 3
acquired-resistance (2) 2
anaplastic lymphoma kinase (2) 2
article (2) 2
cell biology (2) 2
ceritinib (2) 2
crizotinib (2) 2
gefitinib (2) 2
gene expression (2) 2
humans (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - genetics (2) 2
mutation (2) 2
oncology (2) 2
acquired resistance (1) 1
activating mutations (1) 1
alectinib (1) 1
alk (1) 1
anaplastic lymphoma kinase - genetics (1) 1
and nsclc (1) 1
animals (1) 1
antineoplastic agents - therapeutic use (1) 1
biochemistry & molecular biology (1) 1
biology (1) 1
biomarkers, tumor - genetics (1) 1
biomarkers, tumor - metabolism (1) 1
biopsy (1) 1
brigatinib (1) 1
cell line, tumor (1) 1
cell lines (1) 1
cell survival (1) 1
chemotherapy (1) 1
crispr (1) 1
crizotinib - administration & dosage (1) 1
crizotinib - pharmacology (1) 1
drug resistance (1) 1
drug resistance, neoplasm (1) 1
drug-combinations (1) 1
eml4-alk (1) 1
epidermal growth factor (1) 1
epidermal growth factor receptors (1) 1
epithelial-cells (1) 1
erbb receptors - genetics (1) 1
erbb receptors - metabolism (1) 1
erlotinib hydrochloride - therapeutic use (1) 1
ethylnitrosourea - adverse effects (1) 1
feeder cells - cytology (1) 1
female (1) 1
fibroblast growth factor (1) 1
fibroblast growth factor receptor 1 (1) 1
fibroblast growth factor receptors (1) 1
fluorescent antibody technique - methods (1) 1
gene (1) 1
genetics & heredity (1) 1
genomes (1) 1
growth factors (1) 1
growth-factor receptor-3 (1) 1
high-throughput screening assays (1) 1
inhibitor (1) 1
keratin-18 - genetics (1) 1
keratin-18 - metabolism (1) 1
keratin-8 - genetics (1) 1
keratin-8 - metabolism (1) 1
kinases (1) 1
lactams, macrocyclic - administration & dosage (1) 1
lactams, macrocyclic - pharmacology (1) 1
lactams, macrocyclic - therapeutic use (1) 1
lorlatinib (1) 1
lung cancer (1) 1
lung neoplasms - chemically induced (1) 1
lung neoplasms - metabolism (1) 1
lung neoplasms - pathology (1) 1
lung-cancer (1) 1
mesenchyme (1) 1
met amplification (1) 1
metastasis (1) 1
mice (1) 1
models (1) 1
motivation (1) 1
multiple-myeloma (1) 1
neoplasms - classification (1) 1
neoplasms - drug therapy (1) 1
neoplasms - genetics (1) 1
neoplasms - pathology (1) 1
non-small cell lung carcinoma (1) 1
nsclc (1) 1
oncogene proteins, fusion - genetics (1) 1
open-label (1) 1
overcomes crizotinib resistance (1) 1
pathway (1) 1
patient-derived cancer cells (1) 1
personalized medicine (1) 1
piperazines - therapeutic use (1) 1
precision medicine (1) 1
precision medicine - methods (1) 1
primary cell culture - methods (1) 1
protein kinase inhibitors - administration & dosage (1) 1
protein kinase inhibitors - pharmacology (1) 1
protein-tyrosine kinase (1) 1
pyrazoles - therapeutic use (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer
by Yoda, Satoshi and Lin, Jessica J and Lawrence, Michael S and Burke, Benjamin J and Friboulet, Luc and Langenbucher, Adam and Dardaei, Leila and Prutisto-Chang, Kylie and Dagogo-Jack, Ibiayi and Timofeevski, Sergei and Hubbeling, Harper and Gainor, Justin F and Ferris, Lorin A and Riley, Amanda K and Kattermann, Krystina E and Timonina, Daria and Heist, Rebecca S and Iafrate, A. John and Benes, Cyril H and Lennerz, Jochen K and Kenudson, Mari Mino and Engelman, Jeffrey A and Johnson, Ted W and Hata, Aaron N and Shaw, Alice T
Cancer Discovery, ISSN 2159-8274, 06/2018, Volume 8, Issue 6, pp. 714 - 729
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The... 
EML4-ALK | DRUG-COMBINATIONS | GENE | ONCOLOGY | CERITINIB | OVERCOMES CRIZOTINIB RESISTANCE | ALECTINIB | ACQUIRED-RESISTANCE | OPEN-LABEL | ROS1 | CHEMOTHERAPY | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Lung Neoplasms - chemically induced | Humans | Ethylnitrosourea - adverse effects | Drug Resistance, Neoplasm | Lactams, Macrocyclic - pharmacology | Anaplastic Lymphoma Kinase - genetics | Whole Exome Sequencing | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Oncogene Proteins, Fusion - genetics | Crizotinib - pharmacology | Cell Line, Tumor | Crizotinib - administration & dosage | Female | Lactams, Macrocyclic - administration & dosage | Mice | Protein Kinase Inhibitors - pharmacology | Mutation | Index Medicus | ALK | brigatinib | crizotinib | lorlatinib | and NSCLC | Anaplastic lymphoma kinase | ceritinib | acquired resistance | alectinib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care
by Kodack, David P and Farago, Anna F and Dastur, Anahita and Held, Matthew A and Dardaei, Leila and Friboulet, Luc and von Flotow, Friedrich and Damon, Leah J and Lee, Dana and Parks, Melissa and Dicecca, Richard and Greenberg, Max and Kattermann, Krystina E and Riley, Amanda K and Fintelmann, Florian J and Rizzo, Coleen and Piotrowska, Zofia and Shaw, Alice T and Gainor, Justin F and Sequist, Lecia V and Niederst, Matthew J and Engelman, Jeffrey A and Benes, Cyril H
Cell Reports, ISSN 2211-1247, 12/2017, Volume 21, Issue 11, pp. 3298 - 3309
Personalized cancer therapy is based on a patient’s tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis. Here, we aim to... 
NSCLC | patient-derived cancer cells | personalized medicine | LUNG-CANCER | STEM-CELLS | GEFITINIB | ROCK INHIBITOR | EPITHELIAL-CELLS | MODELS | CERITINIB | RESISTANCE | PRECISION MEDICINE | REPROGRAMMED CELLS | CELL BIOLOGY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Primary Cell Culture - methods | Humans | Lung Neoplasms - metabolism | ErbB Receptors - genetics | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Anaplastic Lymphoma Kinase | Neoplasms - genetics | Biomarkers, Tumor - metabolism | Lactams, Macrocyclic - therapeutic use | Tumor Cells, Cultured | Pyridines - therapeutic use | Crizotinib | Lung Neoplasms - genetics | Gene Expression | ErbB Receptors - metabolism | Fluorescent Antibody Technique - methods | Keratin-8 - genetics | Neoplasms - classification | Piperazines - therapeutic use | Receptor Protein-Tyrosine Kinases - metabolism | Keratin-18 - genetics | Neoplasms - drug therapy | High-Throughput Screening Assays | Keratin-8 - metabolism | Receptor Protein-Tyrosine Kinases - genetics | Biopsy | Keratin-18 - metabolism | Feeder Cells - cytology | Biomarkers, Tumor - genetics | Erlotinib Hydrochloride - therapeutic use | Mutation | Neoplasms - pathology | Precision Medicine - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
by Raoof, S and Mulford, IJ and Frisco-Cabanos, H and Nangia, V and Timonina, D and Labrot, E and Hafeez, N and Bilton, SJ and Drier, Y and Ji, F and Greenberg, M and Williams, A and Kattermann, K and Damon, L and Sovath, S and Rakiec, DP and Korn, JM and Ruddy, DA and Benes, CH and Hammerman, PS and Piotrowska, Z and Sequist, LV and Niederst, MJ and Barretina, J and Engelman, JA and Hata, AN
ONCOGENE, ISSN 0950-9232, 09/2019, Volume 38, Issue 37, pp. 6399 - 6413
Evolved resistance to tyrosine kinase inhibitor (TKI)-targeted therapies remains a major clinical challenge. In epidermal growth factor receptor (EGFR) mutant... 
MULTIPLE-MYELOMA | GEFITINIB | METASTASIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | ACQUIRED-RESISTANCE | CELL BIOLOGY | TO-MESENCHYMAL TRANSITION | MET AMPLIFICATION | ONCOLOGY | PATHWAY | GENETICS & HEREDITY | GROWTH-FACTOR RECEPTOR-3 | INHIBITOR | ACTIVATING MUTATIONS | Tyrosine | CRISPR | Fibroblast growth factor | Cell survival | Epidermal growth factor receptors | Small cell lung carcinoma | Mesenchyme | Lung cancer | Non-small cell lung carcinoma | Genomes | Gene expression | Drug resistance | Kinases | Epidermal growth factor | Motivation | Cell lines | Growth factors | Fibroblast growth factor receptor 1 | Protein-tyrosine kinase | Fibroblast growth factor receptors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.